LBA30 Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)
| Autor: | Kurtz, J.E., Pujade-Lauraine, E., Oaknin, A., Belin, L., Tsibulak, I., Cibula, D., Vergote, I.B., Rosengarten, O.S., Rodrigues, M.J., de Gregorio, N., Martinez-Garcia, J., Pautier, P., Mouret Reynier, M.A., Selle, F., D'Hondt, V., Lobbedez, F. Joly, Boissier, E. Bultot, Floquet, A., Heudel, P-E., Heitz, F. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S1397-S1397 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|